Calidi Biotherapeutics (CLDI)

• Market cap: $2.8M
• 1 day: -0.08%
• 5 days: 7.25%
• 1 month: -28.5%
• 3 months: -77.02%
• 6 months: -83.39%
• Year to date: -78.19%
• 1 year: -94.75%
• 5 years: -99.98%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Employees: 29